T. Totev

发表

Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review

Jipan Xie, N. Li, Kristina S Chen, 2019, Journal of medical economics.

Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome

M. Neary, J. Beaumont, D. Cella, 2018, Medicine.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data

G. Joseph, Lei Chen, A. Guérin, 2017, Journal of medical economics.

Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay: A Systematic Review and Meta-Analysis

T. Timbrook, P. Thompson-Leduc, R. Hasbún, 2022, Antibiotics.

Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.

M. Neary, A. Benson, M. Kulke, 2019, The oncologist.

Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.

M. Neary, A. Benson, M. Kulke, 2019, The oncologist.

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey

P. Lefebvre, D. Pilon, M. Zhdanava, 2022, Neuropsychiatric disease and treatment.

Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome

M. Neary, J. Beaumont, D. Cella, 2019, BMC Cancer.

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

R. Ayyagari, O. Patterson-Lomba, F. Mu, 2022, The Journal of Headache and Pain.

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

R. Ayyagari, O. Patterson-Lomba, F. Mu, 2022, The Journal of Headache and Pain.

Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experiment

A. Pickard, A. Mühlbacher, M. Duh, 2016, Journal of Patient-Reported Outcomes.

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

P. Lefebvre, D. Pilon, M. Zhdanava, 2022, Neuropsychiatric disease and treatment.

NDT_A_379985 2003..2019

P. Lefebvre, D. Pilon, M. Zhdanava, 2022 .

Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

G. Demetri, M. Gounder, B. V. Van Tine, 2020, Cancer.

Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR

M. Neary, A. Benson, F. Vekeman, 2017, Journal of medical economics.

DEBATE: ROLE OF RADIATION THERAPY IN ASYMPTOMATIC PATIENT FOR LOCALLY

J. Beaumont, D. Cella, M. Duh, 2017 .

Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study

M. Duh, J. Ivanova, J. Antin, 2020, Annals of Hematology.

Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder

Zheng-Yi Zhou, Shawn X. Sun, J. Signorovitch, 2015, Journal of medical economics.

Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome

M. Neary, J. Beaumont, D. Cella, 2019, BMC cancer.

Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome

D. Metz, P. Lapuerta, V. Joish, 2020, Cancer management and research.

Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

R. Ayyagari, D. Grebennik, T. Totev, 2024, BMC cancer.